SCHEMBL4390874

SCHEMBL4390874

CCO[Si](OCC)(OCC)c1ccc(-c2ccccn2)nc1.CCO[Si](OCC)(OCC)c1ccc(-c2ccccn2)nc1.Cl[Co]Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.40
KDM4E B2RXH2 3/20 0.40
CCR1 P32246 3/20 0.40
CCR5 P51681 3/20 0.40
CCR8 P51685 3/20 0.40
CYP1A2 P05177 2/20 0.40
P4HTM Q9NXG6 2/20 0.40
POLB P06746 1/20 0.40
METAP1 P53582 1/20 0.40
BLM P54132 1/20 0.40
HIF1A Q16665 1/20 0.40
DOHH Q9BU89 1/20 0.40
TP53 P04637 2/20 0.40
ALOX15 P16050 2/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4385997 0.94 KDM4E (0.42) LMNAKDM4ECCR1CCR5CCR8
SCHEMBL4386223 0.94 KDM4E (0.45) LMNAKDM4ECCR1CCR5CCR8
SCHEMBL4385944 0.93 KDM4E (0.41) LMNAKDM4ECCR1CCR5CCR8
SCHEMBL4391990 0.93 KDM4E (0.41) LMNAKDM4ECCR1CCR5CCR8
SCHEMBL4388561 0.91 LMNA (0.40) LMNAKDM4ECCR1CCR5CCR8
SCHEMBL4377427 0.91 LMNA (0.40) LMNAKDM4ECCR1CCR5CCR8
SCHEMBL4390883 0.91 LMNA (0.40) LMNAKDM4ECCR1CCR5CCR8
SCHEMBL4378191 0.91 LMNA (0.40) LMNAKDM4ECCR1CCR5CCR8
SCHEMBL4389353 0.90 KDM4E (0.41) LMNAKDM4ECCR1CCR5CCR8
SCHEMBL4382202 0.89 CCR1 (0.33) CCR1CCR5CCR8HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084608-B2 2,2′ -bipyridine derivative having a reactive silyl group, its production method, and transition metal complex SHIN-ETSU CHEMICAL CO., LTD. (JP) 2011-12-27 US disclosed
US-20090299068-A1 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-12-03 US disclosed
EP-2128165-A1 2, 2´-bipyridine derivatives having reactive silyl group, production methods, transition metal complexes thereof Shin-Etsu Chemical Co., Ltd. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090299068-A1 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX CBR3, TST, HRH3 LMNA 4659/4885KDM4E 3085/4885CCR1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.